| Trial ID: | L4193 |
| Source ID: | NCT01269034
|
| Associated Drug: |
Exenatide
|
| Title: |
New Onset Type 1 Diabetes: Role of Exenatide
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01269034/results
|
| Conditions: |
Type 1 Diabetes
|
| Interventions: |
DRUG: Exenatide|DRUG: Rapid and long acting insulin|DRUG: long acting insulin + rapid acting + 1.25 mcg Exenatide
|
| Outcome Measures: |
Primary: The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia., Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted., February 2013 | Secondary: The Role of Exenatide on Postprandial Glucagon and Gastric Emptying., Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted., February 2013|Postprandial Glucose Excursions, Glucagon Concentrations and Gastric Emptying in Normal Healthy Controls., Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted., February 2013
|
| Sponsor/Collaborators: |
Sponsor: Albert Einstein College of Medicine | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
13
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2010-12
|
| Completion Date: |
2017-01-31
|
| Results First Posted: |
2021-08-04
|
| Last Update Posted: |
2021-08-04
|
| Locations: |
Albert Einstein CRC- West Campus, Bronx, New York, 10467, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01269034
|
